Vor Biopharma Inc. (VOR)

1.6900 -0.0100 (-0.59%) At close: 04:00PM EDT

Vor Biopharma Inc.

100 Cambridgepark Drive
Suite 101
Cambridge, MA 02140
United States
617 655 6580
https://www.vorbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 168

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Robert Ang M.B.A., M.D., MBBS	President, CEO & Director	943.91k	N/A	1975
Dr. Tirtha Chakraborty Ph.D.	Chief Scientific Officer	661.98k	N/A	1973
Dr. Eyal C. Attar M.D.	Chief Medical Officer	660.55k	N/A	1971
Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D.	Scientific Founder & Chairman of Scientific Advisory Board	N/A	N/A	1971
Dr. Nathan D. Jorgensen M.B.A., Ph.D.	Chief Financial Officer	608.48k	N/A	1977
Ms. Tania Philipp	Chief People Officer	N/A	N/A	1972
Dr. Robert G. Pietrusko Pharm. D., Pharm.D.	Chief Regulatory Officer	N/A	N/A	1948
Mr. John C. King M.B.A.	Chief Commercial Officer	N/A	N/A	1976
Mr. Samir Vattompadam M.S.	Senior Vice President of Portfolio Strategy & Program Management	N/A	N/A	N/A
Mr. David Phillips M.B.A.	Senior VP & Head of Quality	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Vor Biopharma Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.